Sequential Imiquimod and Photodynamic Therapy for Actinic Keratosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for actinic keratosis, such as cryosurgery and FDA-approved imiquimod cream, are limited by their effectiveness in addressing both clinical and subclinical lesions, lengthy dosing regimens, and high incidence of application site reactions, failing to provide comprehensive and comfortable solutions for patients.
Innovation Solution
A combination therapy using lower dosage strength imiquimod formulations, such as 2.5% or 3.75% imiquimod cream, in conjunction with photodynamic therapy, applied sequentially or concomitantly to treat actinic keratosis, offering a shorter treatment duration and larger treatment area coverage with reduced application site reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dosage strength imiquimod cream (5%) is used to treat actinic keratosis, then treatment efficacy is improved, but application site reactions increase and treatment duration lengthens
Solution Approach 1:
The patent changes the dosage parameter of imiquimod from the standard 5% concentration to lower concentrations (2.5% or 3.75%), thereby reducing application site reactions while maintaining treatment efficacy when combined with photodynamic therapy. This parameter change allows the treatment to be better tolerated by patients.
Solution Approach 2:
The patent combines imiquimod topical therapy with photodynamic therapy (PDT) into a single treatment regimen. This merging of two therapeutic approaches allows for reduced imiquimod dosage while achieving comparable or superior efficacy to high-dose imiquimod monotherapy, thereby reducing application site reactions.
Solution Approach 3:
The patent implements a treatment regimen with periodic application of imiquimod followed by PDT sessions, rather than continuous high-dose application. This periodic action allows tissue recovery between treatments and reduces cumulative application site reactions while maintaining treatment efficacy.
2Reliability
If lengthy dosing regimens are used to ensure complete clearance of actinic keratosis, then treatment efficacy is improved, but patient compliance deteriorates
Solution Approach 1:
By combining imiquimod therapy with photodynamic therapy into a single integrated regimen, the overall treatment duration is reduced compared to prolonged imiquimod monotherapy. This merging allows for complete clearance of actinic keratosis with a more manageable treatment schedule, improving patient compliance.
Solution Approach 2:
The patent changes the treatment protocol parameters by reducing imiquimod dosage strength and adjusting application frequency to align with PDT sessions. This parameter optimization achieves complete lesion clearance with a shorter overall treatment course, thereby improving patient compliance.
3Adaptability or versatility
If standard imiquimod cream is used to treat both clinical and subclinical lesions, then comprehensive coverage is improved, but treatment duration lengthens and side effects increase
Solution Approach 1:
The patent merges imiquimod topical therapy with photodynamic therapy to create a synergistic regimen that effectively treats both clinical and subclinical actinic keratosis lesions. This combination achieves comprehensive coverage with a reduced treatment duration compared to imiquimod monotherapy.
Solution Approach 2:
By changing the imiquimod dosage parameter to lower concentrations (2.5% or 3.75%) and adjusting the treatment schedule to include PDT sessions, the patent achieves comprehensive coverage of clinical and subclinical lesions with a shorter overall treatment duration and reduced side effects.
4Reliability
If high dosage imiquimod is applied to treat actinic keratosis, then lesion clearance is improved, but treatment cost and complexity increase
Solution Approach 1:
The patent changes the imiquimod dosage parameter from 5% to lower concentrations (2.5% or 3.75%), which simplifies the treatment protocol by reducing the need for extensive monitoring and management of severe application site reactions. This parameter change maintains lesion clearance efficacy while reducing protocol complexity.
Solution Approach 2:
The patent implements a periodic treatment schedule with imiquimod application followed by PDT sessions, creating a structured and manageable protocol. This periodic action simplifies treatment planning and execution compared to continuous high-dose imiquimod application, while achieving complete lesion clearance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy achieves significant clearance of actinic keratosis lesions, including both clinical and subclinical ones, with improved patient compliance and reduced side effects, demonstrating enhanced efficacy and tolerability compared to monotherapy approaches.
Implementation Method 1
administering photodynamic therapy to the treatment area or to an AK lesion in the treatment area
Data Source
AI summary
This disclosure is directed to the use of sequentially applied topical therapy with a lower dosage strength imiquimod composition and photodynamic therapy for treating actinic keratosis, wherein the photodynamic therapy is administered subsequent to the topical therapy with the imiquimod composition. In some embodiments, the imiquimod composition comprises from about 1% (w/w) to about 4.25% (w/w) imiquimod.